Some 4,500 formulations across 60 dosage forms, with 700 APIs and 200 finished products for Western markets will be present at CPhI China
CPhI China, hosted by UBM EMEA and CCCMHPIE and co-organised by UBM Sinoexpo, returns to the Shanghai New International Exhibition Centre (SNIEC) China from 21-23 June 2016. The event is once again held in conjunction with P-MEC China and will co-locate with ICSE, BioPh, Innopack, LABWorld, NEX China, P-Logi, Clean Room & EP, Hi China, co-located with Fi Asia- China.
In the last year, when viewed on a micro-economic scale, it is clear that Chinese pharma is increasingly supporting the entire pharmaceutical value chain, with biopharma in particular seeing government support and investment. The government’s ‘Made in China 2025’ plan listed biomedicine, including gene therapies, monoclonal antibodies and vaccines, as the priority for the industry in the future. The country is also seeking increasing foreign direct investment to supplement its considerable investment capabilities, with the ambitious goal of furthering true innovation in biopharmaceuticals and advanced medicinal products.
China is already the largest producer of APIs, starting materials, critical intermediates and excipients worldwide, producing more than 4,500 different types of pharmaceutical formulations in more than 60 dosage forms. The country is now pushing forwards reforms in the pharmaceutical regulatory reviews and approval systems, with the goal of eliminating the drug application backlog within 2-3 years and enhancing export potential - both to emerging economies and highly regulated markets. Chinese and international pharmaceutical enterprises including Wuxi Apptec, Sinochem, Sartorius, Canaan, Colorcon, Shinva Medical, Truking, De Dietrich, Merck Millipore, Bachem are already confirmed to participate alongside exhibiting alongside a diverse supply chain.
Pharma executives will meet, target prospects and conduct business, while obtaining the latest insight from across a market that is rapidly advancing up the value chain and tightening regulations, but simultaneously, lowering production costs.
CPhI & P-MEC China provide a good platform to harness this diverse market’s considerable opportunities, having evolved and grown alongside the industry for the last 16 years. At the 2016 event the floor space will expand to 150,000m2, accommodating more than 2,800 exhibitors – including art least 1,130 pharma ingredients exhibitors, 400+ biopharmaceutical and natural extracts specialists, 500+ pharma machinery professionals and more than 150 pharmaceutical packaging, materials and drug delivery experts.
The eleven-in-one show brings together in excess of 35,000 attendees from more than 120 countries, including Germany, USA, Italy, Japan, China, Russia, India, Korea and Hong Kong. The entire pharmaceutical supply chain will be present via 12 dedicated product zones: from APIs to outsourcing, CRO/CMO, packaging, biopharmaceuticals, natural extracts, machinery and more.
Beyond the exhibition floor, an extensive four-day programme will include some 182 speakers from China and international thought-leaders, presenting more than 50 seminars, 24 high level forums, and two C-level networking events across three days. The programme has been tailored in conjunction with Pharmaceutical Outsourcing and Pharmaceutical Technology magazines to create an agenda that demonstrates the essential tools to build trust and relationships in China, remove the perceived barriers, and feature trends in the current business and manufacturing environment.
Sessions include the first ‘China - CEEC Business Matchmaking Activities’; ‘2016 International Summit for Pharmaceutical Packaging & Drug Delivery Systems’; the returning ‘P-MEC Summit’; and the third ‘China BioPh Outlook Summit 2016’. Specific topics will outline regulation changes, challenges and opportunities; the current status of the biopharmaceutical industry, new market developments and policy hotspots; and the opportunities of new manufacturing technologies and information/solution systems to uphold and implement GMP standards.
New features of CPhI China 2016 include:
'China has been an increasingly dominant force in pharma for the last decade and already leads in total volumes of APIs and excipients. But we are now seeing an increasingly large number of providers across the full spectrum of the pharma value chain attend at CPhI China,' said Andreas Mavrommatis, Marketing Director at UBM EMEA. 'In particular, biopharmaceuticals, finished product providers, natural extracts and CROs are rapidly expanding.
'At CPhI China we have the largest gathering of the key players and companies from across the industry all looking to maximise opportunities in this huge domestic healthcare economy. But just as crucially, the scope to export pharmaceutical products worldwide.'